Single Cell Genomics of Psoriatic Skin

Elucidating the Fundamental Differences Between HLA-Cw6 Positive and HLA-Cw6 Negative Psoriasis Skin Lesions, With a Comparison to Healthy Skin, at the Single Cell Level of the Infiltrated Immune Cell Types

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02929745

Enrollment

Registered

2016-10-11

Start date

2016-07-01

Completion date

2020-12-09

Last updated

2021-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

immunology, genetics

Brief summary

The purpose of this study is to understand how genetics play a role in psoriasis. Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this study aims to find out how it affects genetic and protein expression in patients with psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry and RNA-sequencing protocol.

Interventions

PROCEDURESkin biopsy

Four 4-5 mm punch biopsies of the skin

PROCEDUREBlood draw

Blood will be drawn to test for HLA-cw6 status

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

For subjects in the psoriasis group: 1. Ability to provide written consent and comply with the protocol 2. At least 18 years of age 3. Diagnosis of plaque psoriasis for at least 6 months prior to enrollment 4. BSA \> 5% and at least one target plaque on trunk or extremities greater than 10cm2 For control subjects: 1. Ability to provide written consent and comply with the protocol 2. At least 18 years of age 3. No previous diagnosis of psoriasis or other inflammatory skin conditions

Exclusion criteria

For subjects in the psoriasis group: 1. Subject has non-plaque form of psoriasis. 2. Subject has drug-induced psoriasis. 3. Pregnancy at any point during the study period. 4. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents. 5. Known HIV positive status. 6. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause. 7. Known coagulopathy. For control subjects: 1. Any physical examination findings by the investigators consistent with psoriasis or other inflammatory skin conditions. 2. Pregnancy at any point during the study period. 3. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents. 4. Known HIV positive status. 5. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause. 6. Known coagulopathy. 7. Use of any immunosuppressant or immunomodulating therapies within 6 months.

Design outcomes

Primary

Measure	Time frame
Determination of immune cell population from skin biopsies	once

Secondary

Measure	Time frame
Determination of diferentially expressed genes from skin biopsies	once
Determination of HLA -cw6 status from blood samples	once

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026